Evidence map›Paper›PMID 34777375›Full record

ArticleFrontiers in immunology2021

Design and Immunological Validation of

Patrick Neckermann, Ditte Rahbaek Boilesen, Torsten Willert, Cordula Pertl, Silke Schrödel, Christian Thirion, Benedikt Asbach, Peter Johannes Holst, Ralf Wagner

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Patrick NeckermannInstitute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
Ditte Rahbaek BoilesenCentre for Medical Parasitology, the Panum Institute, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Torsten WillertSIRION Biotech GmbH, Munich, Germany.
Cordula PertlSIRION Biotech GmbH, Munich, Germany.
Silke SchrödelSIRION Biotech GmbH, Munich, Germany.
Christian ThirionSIRION Biotech GmbH, Munich, Germany.
Benedikt AsbachInstitute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
Peter Johannes HolstCentre for Medical Parasitology, the Panum Institute, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.
Ralf WagnerInstitute of Medical Microbiology & Hygiene, Molecular Microbiology (Virology), University of Regensburg, Regensburg, Germany.
Inprother (Denmark) · DKInstitute of Medical Microbiology and Hygiene · DEUniversity Hospital Regensburg · DEUniversity of Copenhagen · DKUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Persistent human papillomavirus (HPV) infections are causative for cervical neoplasia and carcinomas. Despite the availability of prophylactic vaccines, morbidity and mortality induced by HPV are still too high. Thus, an efficient therapy, such as a therapeutic vaccine, is urgently required. Herein, we describe the development and validation of

Indexed as

Papillomavirus VaccinesA549 CellsAnimalsAntigens, ViralFemaleHEK293 CellsHumansMacaca fascicularisMiceMice, Inbred BALB CPapillomaviridaePapillomavirus InfectionsSpleenViral ProteinsAntigens, ViralPapillomavirus VaccinesViral Proteinsadenoviral vectorDNA vaccineHPVimmunogen designinvariant chainMfPV3therapeutic vaccine

Identifiers

PMID34777375
PMCPMC8581358
OpenAlexW3210045208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.